Nicotine Metabolism-informed Care for Smoking Cessation: A Pilot Precision RCT.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

Varenicline doubles cessation over nicotine replacement therapy (NRT) patch for "normal," but not "slow," nicotine metabolizers, as assessed by the nicotine metabolite ratio (NMR).

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Participants reported perceptions of MIC, underwent blood draw for NMR, and received expert cessation counseling.

For MIC participants, medication selection was informed by NMR result (normal (≥0.31) vs. slow (< 0.31)).

How the Study Was Run

The researchers set it up as a randomized and pilot study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

The primary outcome was MIC feasibility, reflected by attitudes toward MIC and by match rates between NMR and medication.

What Was Measured

Varenicline doubles cessation over nicotine replacement therapy (NRT) patch for "normal," but not "slow," nicotine metabolizers, as assessed by the nicotine metabolite ratio (NMR).

Topics PubMed links to this paper include Nicotine, Nicotinic Agonists, Pilot Projects, Precision Medicine, Smoking Cessation, Smoking Cessation Agents and Tobacco Smoking.

What This Means in Plain Language

The paper is a randomized and pilot study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.